Partial label learning: Taxonomy, analysis and outlook.

Neural Netw

School of Economics and Management, Beijing University of Posts and Telecommunications, Beijing 100876, China.

Published: April 2023

Partial label learning (PLL) is an emerging framework in weakly supervised machine learning with broad application prospects. It handles the case in which each training example corresponds to a candidate label set and only one label concealed in the set is the ground-truth label. In this paper, we propose a novel taxonomy framework for PLL including four categories: disambiguation strategy, transformation strategy, theory-oriented strategy and extensions. We analyze and evaluate methods in each category and sort out synthetic and real-world PLL datasets which are all hyperlinked to the source data. Future work of PLL is profoundly discussed in this article based on the proposed taxonomy framework.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neunet.2023.02.019DOI Listing

Publication Analysis

Top Keywords

partial label
8
label learning
8
taxonomy framework
8
learning taxonomy
4
taxonomy analysis
4
analysis outlook
4
outlook partial
4
label
4
pll
4
learning pll
4

Similar Publications

Introduction: Benralizumab is an interleukin 5-receptor-blocking drug registered for the treatment of eosinophilic asthma. It has proven efficient and safe in a small phase-II trial in hypereosinophilic syndrome and is currently being investigated in a larger, randomized phase-III trial. We report on real-world experience with benralizumab in 15 patients with severe Hypereosinophilic syndrome (HES) that were refractory to other treatments or on unacceptable steroid doses.

View Article and Find Full Text PDF

Background: Even though major improvements have been made in the treatment of myeloma, the majority of patients eventually relapse or progress. Patients with multiple myeloma who relapse after initial high-dose chemotherapy with autologous stem cells have a median progression free survival up to 2-3 years, depending on risk factors such as previous remission duration. In recent years, growing evidence has suggested that allogeneic stem cell transplantation could be a promising treatment option for patients with relapsed or progressed multiple myeloma.

View Article and Find Full Text PDF

Malaria remains a global health concern, with 249 million cases and 608,000 deaths being reported by the WHO in 2022. Traditional diagnostic methods often struggle with inconsistent stain quality, lighting variations, and limited resources in endemic regions, making manual detection time-intensive and error-prone. This study introduces an automated system for analyzing Romanowsky-stained thick blood smears, focusing on image quality evaluation, leukocyte detection, and malaria parasite classification.

View Article and Find Full Text PDF

Background: Neuroendocrine carcinomas (NECs) are treated with a frontline platinum-etoposide combination with no standard second-line therapies. We explored a novel combination of nanoliposomal irinotecan (Nal-IRI), 5-fluorouracil (5-FU), and leucovorin (LV) in advanced refractory NECs and investigated the impact of UGT1A1*28 polymorphism on treatment outcomes and toxicity.

Methods: We conducted an open-label, single-arm, multi-center Phase 2 trial in advanced NEC patients of gastroenteropancreatic (GEP) or unknown origin with progression or intolerance to first-line therapy.

View Article and Find Full Text PDF

The presence of circulating tumor cell (CTC) clusters is associated with disease progression and reduced survival in a variety of cancer types. In breast cancer, preclinical studies showed that inhibitors of the Na/K ATPase suppress CTC clusters and block metastasis. Here we conducted a prospective, open-label, proof-of-concept study in women with metastatic breast cancer, where the primary objective was to determine whether treatment with the Na/K ATPase inhibitor digoxin could reduce mean CTC cluster size.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!